Related Experiment Video
Updated: Aug 6, 2025
Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
Published on: June 7, 2015
Radionuclide-based theranostics - a promising strategy for lung cancer
Tianxing Zhu1,2, Jessica C Hsu3, Jingpei Guo4
1Department of Respiratory Medicine, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu, 322000, Zhejiang, China.
Purpose:
This review aims to provide a comprehensive overview of the latest literature on personalized lung cancer management using different ligands and radionuclide-based tumor-targeting agents.
Background:
Lung cancer is the leading cause of cancer-related deaths worldwide. Due to the heterogeneity of lung cancer, advances in precision medicine may enhance the disease management landscape. More recently, theranostics using the same molecule labeled with two different radionuclides for imaging and treatment has emerged as a promising strategy for systemic cancer management. In radionuclide-based theranostics, the target, ligand, and radionuclide should all be carefully considered to achieve an accurate diagnosis and optimal therapeutic effects for lung cancer.
Methods:
We summarize the latest radiotracers and radioligand therapeutic agents used in diagnosing and treating lung cancer. In addition, we discuss the potential clinical applications and limitations associated with target-dependent radiotracers as well as therapeutic radionuclides. Finally, we provide our views on the perspectives for future development in this field.
Conclusions:
Radionuclide-based theranostics show great potential in tailored medical care. We expect that this review can provide an understanding of the latest advances in radionuclide therapy for lung cancer and promote the application of radioligand theranostics in personalized medicine.
Insights
Personalized lung cancer management is advancing with radionuclide-based theranostics. This review covers new radioligands and agents for precise diagnosis and treatment, improving patient outcomes.
Area of Science:
- Oncology
- Nuclear Medicine
- Radiopharmaceutical Chemistry
Background:
- Lung cancer remains a leading cause of cancer mortality globally.
- Tumor heterogeneity necessitates personalized treatment approaches.
- Theranostics, combining imaging and therapy with radionuclides, offers a promising strategy for systemic cancer management.
Purpose of the Study:
- To provide a comprehensive review of recent literature on personalized lung cancer management.
- To focus on the application of various ligands and radionuclide-based tumor-targeting agents.
- To highlight advances in precision medicine for lung cancer.
Main Methods:
- Summarizing current radiotracers and radioligand therapeutic agents for lung cancer diagnosis and treatment.
- Discussing clinical applications and limitations of target-dependent radiotracers.
- Reviewing therapeutic radionuclides and their role in personalized medicine.
Main Results:
- Radionuclide-based theranostics demonstrate significant potential for tailored cancer care.
- Recent advances include novel radioligands and radionuclide agents for lung cancer.
- Careful consideration of target, ligand, and radionuclide is crucial for effective lung cancer theranostics.
Conclusions:
- Radionuclide-based theranostics hold great promise for personalized lung cancer management.
- This review aims to enhance understanding of the latest radionuclide therapies for lung cancer.
- The study promotes the wider application of radioligand theranostics in precision oncology.
Related Concept Videos
01:13Radiological Investigation III: Pulmonary Angiogram and PET Scan
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...
01:25Imaging Studies II: Positron Emission Tomography and Scintigraphy
Fundamental Principles of PET